Phase 2 trial launches for combination stem-cell treatment for ischemic HF – Healio
|
Phase 2 trial launches for combination stem–cell treatment for ischemic HF
Healio The phase 2, randomized, blinded, placebo-controlled CONCERT trial will study a combination of autologous bone marrow derived mesenchymal cells and endomyocardial biopsy derived c-kit+ cardiac stem cells. The trial will enroll 160 patients across seven … |
